Publication List
Return to: [Masahide Kuroki, M.D. & Ph.D. (Japanese) or (English)]
  1. Shirasu, N. and Kuroki, Ma.: Simultaneous genotyping of single nucleotide polymorphisms in alcoholism-related genes using duplex and triplex allele-specific PCR with two-step thermal cycles. Anal. Sci., 30(11): 1093-1096, 2014.
  2. Nam, S. O., Yotsumoto, F., Miyata, K., Suzaki, Y., Yagi, H., Odawara, T., Manabe, S., Ishikawa, T., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Anticancer Res., 34(8): 4615-4620, 2014.
  3. Kuroki, Ma. and Shirasu, N.: Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens. Anticancer Res., 34(8): 4481-4488, 2014.
  4. Napathorn S. C., Kuroki, Mo. and Kuroki, Ma.: High expression of fusion proteins consisting of a single-chain variable fragment antibody against a tumor-associated antigen and interleukin-2 in Escherichia coli. Anticancer Res., 34(8): 3937-3946, 2014.
  5. Anuleejun, S., Palaga, T., Katakura, Y., Kuroki, Mo., Kuroki, Ma. and Napathorn S. C.: Optimal production of a fusion protein consisting of a single-chain variable fragment antibody against a tumor-associated antigen and interleukin-2 in fed-batch culture of Pichia pastoris. Anticancer Res., 34(8): 3925-3935, 2014.
  6. Shirasu, N., Yamada, H., Shibaguchi, H., Kuroki, Mo. and Kuroki, Ma.: Potent and specific antitumor effect of CEA-targeted photoimmunotherapy. Int. J. Cancer, 135 (11):2697-2710, 2014.
  7. Miyata, K., Yotsumoto, F., Nam, S. O., Odawara, T., Manabe, S., Ishikawa, T., Itamochi, T., Kigawa, J., Takada, S., Asahara, H., Kuroki, Ma. and Miyamoto, S.: Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. Cancer Medicine, 3 (5): 1159-1169, 2014.
  8. Hanaoka, H., Kuroki, Ma., Yamaguchi, A., Achmad, A., Iida, Y., Higuchi, T., Oriuchi, N., Tsushima, Y. and Endo, K.: Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother. Radiopharm., 29(2): 70-76, 2014.
  9. Zhang, B. Kawachi, E., Miura, S., Uehara, Y., Matsunaga, A., Kuroki, Ma. and Saku, K.: Therapeutic approaches to the regulation of HDL metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise. Circ. J., 77(11): 2651-2663, 2013.
  10. Nam, S O., Yotsumoto, F., Miyata, K., Shirasu, N., Miyamoto, S and Kuroki, Ma.: Possible therapeutic targets among the molecules involved in the warburg effect in tumor cells. Anticancer Res., 33 (7): 2855-2860, 2013.
  11. Shirasu, N., Nam, S O. and Kuroki, Ma.: Tumor-targeted photodynamic therapy. Anticancer Res., 33 (7): 2823-2831, 2013.
  12. Yotsumoto, F., Tokunaga, E., Oki, E., Maehara, Y., Yamada, H., Nakajima, K., Nam, S. O., Miyata, K., Koyanagi, M., Doi, K., Shirasawa, S., Kuroki, Ma. and Miyamoto, S.: Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. Mol Cancer Res. 11(5): 506-517, 2013.
  13. Uchida, H., Marzulli, M., Nakano, K., Goins, W. F., Chan, J., Hong, C. S., Mazzacurati, L., Yoo, J. Y., Haseley, A., Nakashima, H., Baek, H., Kwon, H., Kumagai, I., Kuroki, Ma., Kaur, B., Chiocca, E. A., Grandi, P., Cohen, J. B. and Glorioso, J. C.: Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol. Ther., doi:10.1038/mt.2012.211, 2012.
  14. Zhang, B., Kawachi, E., Matsunaga, A., Imaizumi, S., Noda, K., Uehara, Y., Miura, S., Yoshinaga, K., Kuroki, Ma. and Saku, K.: Reactivity of direct assays for Low-Density Lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia. Circ. J., 76(9): 2241-2248, 2012.
  15. Tsuru, H., Shibaguchi, H., Kuroki, Mo., Yamashita, Y. and Kuroki, Ma.: Tumor growth inhibition by sonodynamic therapy using a novel sonosensitizer. Free Radic. Biol. Med., 53 (3): 464-472, 2012. （A Doctor's Thesis of Tsuru, H.）
  16. Shirasu, N. and Kuroki, Ma.: Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Anticancer Res., 32 (6): 2377-2383, 2012.
  17. Miyata, K., Yotsumoto, F., Nam, S O., Kuroki, Ma. and Miyamoto, S.: Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer. Anticancer Res., 32 (6): 2347-2352, 2012.
  18. Yoshida, Y., Tsunoda, T., Doi, K., Fujimoto, T., Tanaka, Y., Ota, T., Ogawa, M., Matsuzaki, H., Kuroki, Ma., Iwasaki, A. and Shirasawa, S.: ALPK2 is Crucial for Luminal Apoptosis and DNA Repair-related Gene Expression in a Three-dimensional Colonic-crypt Model. Anticancer Res., 32 (6): 2301-2308, 2012. （A Doctor's Thesis of Yoshida, Y.）
  19. Ota, T., Doi, K., Fujimoto, T., Tanaka, Y., Ogawa, M., Matsuzaki, H., Kuroki, Ma., Miyamoto, S., Shirasawa, S. and Tsunoda, T.: KRAS Up-regulates the Expression of miR-181a, miR-200c and miR-210 in a Three-dimensional-specific Manner in DLD-1 Colorectal Cancer Cells. Anticancer Res., 32 (6): 2271-2275, 2012. （A Doctor's Thesis of Ohta, T.）
  20. Kuroki, Ma., Miyamoto, S., Morisaki, T., Yotsumoto, F., Shirasu, N., Taniguchi, Y. and Soma, G.： Biological response modifiers used in cancer biotherapy. Anticancer Res., 32 (6): 2229-2233, 2012.
  21. Shibaguchi, H., Tsuru H., Kuroki, Mo. and Kuroki, Ma.: Enhancement of the antitumor effect on combination therapy of an anticancer drug and its antibody against carcinoembryonic antigen. Chemotherapy, 58(2):110-117, 2012.
  22. Shirasu, N., Yamada, H., Shibaguchi, H., Kuroki, Mo. and Kuroki, Ma.: Molecular characterization of a fully human chimeric T cell antigen receptor for tumor-associated antigen EpCAM. J. Biomed. Biotechnol., doi:10.1155/2012/853879, 2012.
  23. Tsunoda, T., Ota, T., Fujimoto, T., Doi, K., Tanaka, Y., Yoshida, Y., Ogawa, M., Matsuzaki, H., Hamabashiri, M., Tyson, D. R., Kuroki, Ma., Miyamoto, S. and Shirasawa, S.: Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol. Cancer, 11(1): 46, 2012.
  24. Doi, K., Fujimoto, T., Okamura, T., Ogawa, M., Tanaka, Y., Mototani, Y., Goto, M., Ota, T., Matsuzaki, H., Kuroki, Ma., Tsunoda, T., Sasazuki, T. and Shirasawa, S.: ZFAT plays critical roles in peripheral T cell homeostasis and its T cell receptor-mediated response. Biochem. Biophys. Res. Commun., doi: 10.1016/j.bbrc.2012.07.065, 2012.
  25. Fujimoto, T., Machida, T., Tsunoda, T., Doi, K., Ota, T., Kuroki, Ma. and Shirasawa, S.: Determination of the critical region of KRAS-induced actin-interacting protein for the interaction with inositol 1,4,5-trisphosphate receptor. Biochem. Biophys. Res. Commun., 408 (2): 282-286, 2011.
  26. Fujimoto, T., Machida, T., Tsunoda, T., Doi, K., Ota, T., Kuroki, Ma. and Shirasawa, S.: KRAS-induced actin-interacting protein regulates inositol 1,4,5-trisphosphate-receptor-mediated calcium release. Biochem. Biophys. Res. Commun., 408 (2): 214-217, 2011.
  27. Fujimoto, T., Machida, T., Tanaka, Y., Tsunoda, T., Doi, K., Ota, T., Okamura, T., Kuroki, Ma. and Shirasawa, S.: KRAS-induced actin-interacting protein is required for the proper localization of inositol 1,4,5-trisphosphate receptor in the epithelial cells. Biochem. Biophys. Res. Commun., 407 (2): 438-443, 2011.
  28. Tsujioka, H., Yotsumoto, F., Hikita, S., Ueda, T., Kuroki, Ma. and Miyamoto, S.: Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Curr. Opin. Obstet. Gynecol., 23: 24-30, 2011.
  29. Nakata, K., Taniguchi, Y., Yoshioka, N., Yoshida, A., Inagawa, H., Nakamoto, T., Yoshimura, H., Miyake, S., Kohchi, C., Kuroki, Ma. and Soma, G.: A mixture of Salacia oblonga extract and IP-PA1 reduces fasting plasma glucose (FPG) and low-density lipoprotein (LDL) cholesterol levels. Nutr Res Pract., 5 (5): 435-442, 2011.
  30. Choijamts, B., Jimi, S., Kondo, T., Naganuma, Y., Matsumoto, T., Kuroki, Ma., Iwasaki, H. and Emoto, M.: CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma (malignant mixed Mullerian tumor). Stem Cells., 29: 1485-1495, 2011. （A Doctor's Thesis of Choijamts, B.）
  31. Hikita, S., Yotsumoto, F., Fumaki, T, Horiuchi, S., Sanui, A., Miyata, K., Nam, S., Tsujioka, H., Ueda, T., Shirota, K., Yoshizato, T., Maeda, K., Ishikawa, T., Okuno, Y., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Res., 31 (7): 2553-2560, 2011.
  32. Yoshida, Y., Tsunoda, T., Doi, K., Tanaka, Y., Fujimoto, T., Machida, T., Ota, T., Koyanagi, M., Takashima, Y., Sasazuki, T., Kuroki, Ma., Iwasaki, A. and Shirasawa, S.: KRAS-mediated upregulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res., 31 (7): 2535-2540, 2011.
  33. Ohmura, T., Fukushima, T., Shibaguchi, H., Yoshizawa, S., Inoue, T., Kuroki, Ma., Sasaki, K. and Umemura, S.: Sonodynamic therapy with 5-aminolevulinic acid and focused ultrasound for deep-seated intracranial glioma in rat. Anticancer Res., 31 (7): 2527-2534, 2011. （A Doctor's Thesis of Ohmura, T.）
  34. Higashi, D., Futami, K., Ishibashi, Y., Egawa, Y., Maekawa, T., Matsui, T., Iwashita, A. and Kuroki, Ma.: Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res., 31 (7): 2499-2504, 2011.
  35. Kunami, N., Yotsumoto, F., Ishitsuka, K., Fukami, T., Odawara, T., Manabe, S., Ishikawa, T., Tamura, K., Kuroki, Ma. and Miyamoto, S.: Anti-tumor effects of CRM197, a specific inhibitor for HB-EGF, in T-cell acute lymphoblastic leukemia. Anticancer Res., 31 (7): 2483-2488, 2011. （A Doctor's Thesis of Kunami, N.）
  36. Tsujioka, H., Fukami, T., Yotsumoto, F., Ueda, T., Hikita, S., Takahashi, Y., Kondo, H., Kuroki, Ma. and Miyamoto, S.: A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res., 31 (7): 2461-2466, 2011.
  37. Tsunoda, T., Takashima, Y., Yoshida, Y., Doi, K., Tanaka, Y., Fujimoto, T., Ota, T., Koyanagi, M., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific manner in colorectal cancer cells. Anticancer Res., 31 (7): 2453-2460, 2011.
  38. Shibaguchi, H., Tsuru, H., Kuroki, Mo. and Kuroki, Ma.: Sonodynamic cancer therapy: a non-invasive and repeatable approach using low-intensity ultrasound with a sonosensitizer. Anticancer Res., 31 (7): 2425-2430, 2011.
  39. Baek, H., Uchida, H., Jun, K., Kim, J. H., Kuroki, Ma., Cohen, J. B., Glorioso J. C. and Kwon, H.: Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells. Molecular Therapy 19, 507-514, 2011.
  40. Doi, K., Fujimoto, T., Koyanagi, M., Tsunoda, T., Tanaka, Y., Yoshida, Y., Takashima, Y., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: ZFAT is a critical molecule for cell survival in mouse embryonic fibroblasts. Cell Mol. Biol. Lett.,16 (1): 89-100, 2011.
  41. Yoshida, Y., Tsunoda, T., Takashima, Y., Fujimoto, T., Doi, K., Sasazuki, T., Kuroki, Ma., Iwasaki, A. and Shirasawa S. ZFAT is essential for endothelial cell assembly and the branch point formation of capillary-like structures in an angiogenesis model. Cell Mol. Biol. Lett., 15 (4): 541-550, 2010.
  42. Yotsumoto, F., Fukami, T., Yagi, H., Funakosi, A., Yoshizato, T., Kuroki, Ma. and Miyamoto, S.: Amphiregulin regulates the activation of ERK and Akt through EGFR and HER3 signals involved in the progression of pancreatic cancer. Cancer Sci., 101 (11): 2351-2360, 2010.
  43. Tsujioka, H., Yotsumoto, F., Shirota, K., Horiuchi, S., Yoshizato, T., Kuroki, Ma. and Miyamoto, S.: Emerging strategies for ErbB ligand-based targeted therapy for cancer. Anticancer Res., 30 (8): 3107-3112, 2010.
  44. Sanui, A., Yotsumoto, F., Tsujioka, H., Fukami, T., Horiuchi, S., Shirota, K., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Miyamoto, S.: HB-EGF inhibition in combination with various anticancer agents enhances its antitumor effects in gastric cancer. Anticancer Res., 30 (8): 3143-3150, 2010. （A Doctor's Thesis of Sanui, A.）
  45. Tsujioka, H., Hachisuga, T., Hikita, S., Ueda, T., Yotsumoto, F., Shirota, K., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Miyamoto, S.: Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations. Anticancer Res., 30 (8): 3119-3123, 2010.
  46. Yotsumoto, F., Oki, E., Tokunaga, E., Maehara, Y., Kuroki, Ma., Hiroto Mizushima, H., Mekada, E., Miyamoto, S.: HB-EGF orchestrates the signals involved in triple-negative and trastuzumab-resistant breast cancer. Int. J. Cancer, 127 (11): 2707-2717, 2010.
  47. Tsunoda, T., Takashima, Y., Tanaka, Y., Fujimoto, T., Doi, K., Hirose, Y., Koyanagagi, M., Yoshida, Y., Okamura, T., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Immune-related zinc finger gene ZFAT is an essential transcriptional regulator for hematopoietic differentiation in blood islands. Proc. Natl. Acad. Sci. USA, 107 (32):14199-14204 2010.
  48. Shirasu, N., Shibaguchi, H., Kuroki, Mo., Yamada, H. and Kuroki, Ma.: Construction and molecular characterization of human chimeric T cell antigen receptors specific for carcinoembryonic antigen. Anticancer Res., 30 (7): 2731-2738 2010.
  49. Tsunoda, T., Takashima, Y., Fujimoto, T., Koyanagi, M., Yoshida, Y., Doi, K., Tanaka, Y., Kuroki, Ma., Sasazuki, T. and Shirasawa, S.: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia, 12: 397-404, 2010.
  50. Yanagisawa, J., Shiraishi, T., Iwasaki, A., Maekawa, S., Higuchi, T., Hiratuka, M., Tanaka, T., Shibaguchi, H., Kuroki, Ma. and Shirakusa, T.: PPARalpha ligand WY14643 reduced acute rejection after rat lung transplantation with the upregulation of IL-4, IL-10 and TGFbeta mRNA expression. J. Heart Lung Transpl., 28: 1172-9, 2009.（A Doctor's Thesis of Yanagisawa, J.）
  51. Mizoe, Y., Shioi, N., Terada, S., Uchida, Y., Kuroki, Ma. and Lee, S.:Characteristic difference of biological activity between Arg-containing and Lys-containing peptide.  In: Peptide Science 2009. (K. Okamoto, ed.), The Japanese Peptide Society (Fukuoka), pp. 213-216, 2010.
  52. Ikeda, T., Nakayama, Y., Hamada, Y., Takeshita, M., Iwasaki, H., Maeshiro, K., Yamashita, Y., Kuroki, Ma. and Ikeda, S.: FU-MK-1 expression in human gallbladder carcinoma: An antigenic prediction marker for a better postsurgical prognosis. Am. J. Clin. Pathol., 132: 111-117, 2009. （A Doctor's Thesis of Ikeda, T.）
  53. Tanaka, T., Shibaguchi, H., Maekawa, S., Shimura, H., Tamura, K. and Kuroki, Ma.: Recent developments in cancer gene therapy with adenovirus vectors. Trends Cancer Res., 5: 63-69, 2009.
  54. Shibaguchi, H. Tanaka, T., Luo, N. and Kuroki, Ma.: Engineering T cells in cancer immunotherapy: strategy for gene construction and antitumor activity. Trends Cancer Res., 5: 21-27, 2009.
  55. Yotsumoto, F., Sanui, A., Fukami, T., Shirota, K., Horiuchi, S., Tsujioka, H., Yoshizto, T., Kuroki, Ma. and Miyamoto, S.: Efficacy of ligand-based targeting for the EGF system in cancer. Anticancer Res., 29: 4879-4885, 2009.
  56. Kuroki, Ma.: A solid-phase mutual inhibition assay with labeled antigen.  In: Methods in Molecular Biology, Vol. 524, Epitope Mapping Protocols (U. Reineke and M. Schutkowski, eds.), Humana Press, Totowa, NJ, pp. 59-66, 2009.
  57. Fukami T., Yoshizato T., Miyamoto S., Yagi H., Yotsumoto F., Nabeshima K., Hachisuga T., Kuroki Ma. and Kawarabayashi T.: Amphiregulin regulates the production of human chorionic gonadotropin in trophoblasts. Life Sci., 84: 796-804, 2009. （A Doctor's Thesis of Fukami, T.）
  58. Yagi, H., Yotsumoto, F., Sonoda, K., Kuroki, Ma., Mekada, E. and Miyamoto, S.: Synergistic anti-tumor effect of paclitaxel with CRM197, an inhibitor of HB-EGF, in ovarian cancer. Int. J. Cancer, 124: 1429-1439, 2009.
  59. Miyamoto, S., Fukami, T., Yagi, H., Kuroki, Ma. and Yotsumoto, F.: Potential for molecularly targeted therapy against epidermal growth factor receptor ligands. Anticancer Res., 29: 823-830, 2009.
  60. Huo, Q., Kinugasa, T., Wang, L., Huang, J., Shibaguchi, H., Kuroki, Mo., Tanaka, T., Yamashita, Y., Nabeshima, K., Iwasaki, H and Kuroki, Ma.: Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Res., 29: 851-858, 2009.
  61. Ide, H., Aoki, N., Terada, S., Uchida, Y., Kuroki, Ma. and Lee, S.: Design and synthesis of Arg-containing-peptides having various secontary structures and their biiological activites.  In: Peptide Science 2008. (M. Nomizu, ed.), The Japanese Peptide Society (Tokyo), pp. 223-226, 2009.
  62. Zhao, J., Kuroki, Mo., Shibaguchi, H., Wang, L., Huo, Q., Takami, N., Tanaka, T., Kinugasa, T. and Kuroki, Ma.: Recombinant human monoclonal IgA antibody against CEA to recruit neutrophils to CEA-expressing cells. Oncol. Res., 17: 217-222, 2008.
  63. Maekawa, S., Iwasaki, A., Shirakusa, T., Kawakami, T., Yanagisawa, J., Tanaka, T., Shibaguchi, H., Kinugasa, T., Kuroki, Mo. and Kuroki, Ma.: Association between the expression of chemokinereceptors CCR7 and CXCR3, and lymph nodemetastatic potential in lung adenocarcinoma. Oncol. Rep., 19: 1461-1468, 2008.（A Doctor's Thesis of Maekawa, S.）
  64. Uchida, H., Kuroki, Mo., Shitama, T., Hayashi, H. and Kuroki, Ma.: Activation of TGF-b1 through up-regulation of TSP-1 by retinoic acid in retinal pigment epithelial cells. Curr. Eye Res., 33: 199-203, 2008.
  65. Huo, Q., Kinugasa, T., Tanaka, T., Zhao, J. and Kuroki, Ma.: Analysis of the expression of tight junction-associated proteins in colorectal cancer. Mol. Tumor Marker Res., 23: 27-28, 2008.
  66. Uchino, J., Takayama, K., Harada-Ikegami, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, Ma. and Nakanishi, Y.: Tumor targeting carboxylesterase fused with anti CEA scFv improve the anticancer effect with a less toxic dose of irinotecan. Cancer Gene Ther., 14: 15: 94-100, 2008.
  67. Tanaka, T., Hamada, H., Kuroki, Mo., Kato, K., Zhao, J., Kinugasa, T., Shibaguchi, H. and Kuroki, Ma.: Application of antibody for targeting of cancer gene therapy. Current Trends Immunol., 8: 27-33, 2007.
  68. Maekawa, S., Iwasaki, A., Enatsu, S., Kawakami, T., Kuroki, Mo., Kuroki, Ma. and Shirakusa, T.: Correlation between lymph node metastasis and expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res., 27: 3735-3741, 2007.
  69. Kinugasa, T., Huo, Q., Higashi, D., Shibaguchi, H., Kuroki, Mo., Tanaka, T., Futami, K., Yamashita, Y., Hachimine, K., Maekawa, S., Nabeshima, K., Iwasaki, H. and Kuroki, Ma.: Selective up-regulation of Claudin-1 and Claudin-2 in colorectal cancer. Anticancer Res., 27: 3729-3733, 2007.
  70. Miyamoto, S., Yagi, H., Yotsumoto, F., Horiuchi, S., Yoshizato, T., Kawarabayashi, T., Kuroki, Ma. and Mekada, E.: New approach to cancer therapy: heparin binding-epidermal growth factor-like growth factor as a novel targeting molecule. Anticancer Res., 27: 3713-3722, 2007.
  71. Tanaka, T., Kuroki, Mo., Hamada, H., Kato, K., Kinugasa, T., Shibaguchi, H., Zhao, J. and Kuroki, Ma.: Cancer-targeting gene therapy using tropism-modified adenovirus. Anticancer Res., 27: 3679-3684, 2007.
  72. Kuroki, Ma., Hachimine, K., Abe, H., Shibaguchi, H., Kuroki, Mo., Maekawa, S., Yanagisawa, J., Kinugasa, T., Tanaka, T. and Yamashita, Y.: Sonodynamic therapy of cancer using novel sonosensitizers. Anticancer Res., 27: 3673-3678, 2007.
  73. Tanaka, T., Hamada, H., Kuroki, Mo., Kato, K., Kinugasa, T., Shibaguchi, H. and Kuroki, Ma.: Targeting strategies by coupling of adenovirus vector and antibody for cancer gene therapy. In: Recent Developments in Gene Therapy, 2007. (J. Xiang, ed.), Transworld Research Network, Kerala (India), pp. 319-326, 2007.
  74. Hachimine, K., Shibaguchi, H., Kuroki, Mo., Yamada, H., Kinugasa, T., Nakae, Y., Asano, R., Sakata, I., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Sonodynamic therapy of cancer using a novel porphyrin derivative, DCPH-P-Na(I), which is devoid of photosensitivity. Cancer Sci., 98: 916-920, 2007.（A Doctor's Thesis of Hachimine, K.）
  75. Huang, J., Shibaguchi, H., Kuroki, Mo., Hirose, Y., Yamada, H., Zhao, J., Kinugasa, T. and Kuroki, Ma.: Subclass conversion from IgG4 to IgG1 of a novel human anti-CEA antibody for increasing its biological activity. Mol. Tumor Marker Res., 21: 53-54, 2006.
  76. EL-Meghawry EL-Kenawy, A., EL-Kott, A.F., Hamed, S.M., Kuroki, Ma.: Prognostic value of carcinoma-associated antigen MK-1 in urinary bladder carcinoma. Int. J. Biol. Markers, 21: 170-174, 2006.
  77. Hamada, Y., Nakayama, Y., Mizoguchi, M., Ikeda, S., Kuroki, Ma. and Iwasaki, H.: MK-1 expression in carcinoma of the ampulla of Vater as a predictor of improved prognosis after surgical resection. Cancer Lett., 243: 211-216, 2006.
  78. Sasaki, T., Ikeda, H., Sato, M., Ohkuri, T., Abe, H., Kuroki, Ma., Onodera, M., Miyamoto, M., Kondo, S. and Nishimura, T.: Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells. Cancer Sci., 97: 920-927, 2006.
  79. Huang, J., Shibaguchi, H. and Kuroki, Ma.: Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity. Chin. J. Cell. Mol. Immunol., 22: 650-653, 2006.
  80. Tokunaga, I., Lee S., Yamada, H., Kuroki, Mo. and Kuroki, Ma.: Effect of innovation of D-anino acids into novel anti-tumor peptide and protein on their conformation and cytotoxicities. In: Peptide Science 2005. (T. Wakamiya, ed.), The Japanese Peptide Society (Osaka), pp. 213-216, 2006.
  81. Tanaka, T., Huang, J., Hirai, S., Kuroki, Mo., Kuroki, Ma., Watanabe, N., Kato, K. and Hamada, H.: CEA-targeted selective gene therapy for gastric cancer through FZ33 fiber modified adenovirus vector. Clin. Cancer Res., 12: 3803-3813, 2006.
  82. Shibaguchi, H., Luo, N., Kuroki, Mo., Zhao, J., Huang, J., Hachimine, K., Kinugasa, T. and Kuroki, Ma.: A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells. Anticancer Res., 26: 4067-4072, 2006.
  83. Kuroki, Ma., Huang, J., Shibaguchi, H., Tanaka, T., Zhao, J., Luo, N., Hachimine, K., Kinugasa, T., Maekawa, S., Enatsu, S., Hamanaka, W., Fukami, T. and Kuroki, Mo.: Possible applications of antibodies or their genes in cancer therapy. Anticancer Res., 26: 4019-4026, 2006.
  84. Enatsu, S., Iwasaki, A., Shirakusa, T., Kawakami, T., Hamasaki M., Nabeshima, K., Iwasaki , H., Maekawa, S., Kuroki, Mo. and Kuroki, Ma.: Expression of hypoxia-inducible factor-1 alpha and its prognostic significance in small-sized adenocarcinomas of the lung. Eur. J. Cardio-Thorac. Surg., 29: 891-895, 2006.（A Doctor's Thesis of Enatsu, S.）
  85. Huang, J., Shibaguchi, H., Zhao, J., Luo, N., Kuroki, Mo., Kinugasa, T., Hirose, Y., Yamada, H. and Kuroki, Ma.: IgG isotype conversion of a novel human anti-carcinoembyonic antigen antibody to increase its biological activity. Anticancer Res., 26: 1057-1064, 2006.
  86. Kinugasa, T., Kuroki, Mo., Toyohara, T., Morita, N., Kuromizu, J., Yamashita, Y., Shirakusa, T., Shibaguchi, H. and Kuroki, Ma.: Granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis patients: a useful tool for surgical indication assessments. Med. Bull. Fukuoka Univ., 33: 283-291, 2006.
  87. Kuroki, Mo., Yamada, H., Shibaguchi, H., Hachimine, K., Hirose, Y., Kinugasa, T., Ishida, I. and Kuroki, Ma.: Preparation of human IgG and IgM monoclonal antibodies for MK-1/Ep-CAM by using human immunoglobulin gene-transferred mouse and gene cloning of their variable regions. Anticancer Res., 25: 3733-3740, 2005.
  88. Kuroki, Ma., Hachimine, K., Huang, J., Shibaguchi, H., Kinugasa, T., Maekawa, S., and Kuroki, Mo. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to tumors with antibody activity. Anticancer Res., 25: 3725-3732, 2005.
  89. Higuchi, T., Shiraishi, T., Hirayama, S., Shibaguchi, H., Kuroki, Mo., Hiratsuka, M., Yamamoto, S., Iwasaki, A., Kuroki, Ma., and Shirakusa, T.: Prevention of acute lung allograft rejection in rat by the Janus kinase 3 inhibitor, Tyrphostin AG490. J. Heart Lung Transplant., 24: 1557-1564, 2005.（A Doctor's Thesis of Higuchi, T.）
  90. Kuroki, Ma., Shibaguchi, H., Kuroki, Mo., Kinugasa, T., Hachimine, K., Enatsu, S., Maekawa, S., Huang, J. and Zhao, J.: Targeting of cancer gene therapy with antibodies or their genes against tumor-associated antigens. Gene Ther. Mol. Biol., 9: 107-112, 2005.
  91. Shirota, K., Tateishi, K., Emoto, M., Hachisuga, T., Kuroki, Ma. and Kawarabayashi, T.: Relaxin-induced angiogenesis in ovary contributes to follicle development. Ann. New Yok Acad. Sci., 1041: 144-146, 2005.
  92. Ohtsuka, K., Kuroki, Ma., Nojima, T., Waki, M. and Takenaka, S.: Interaction analysis of the carcinoembryonic antigen (CEA) with its monoclonal antibody immobilized on a gold surface using fourier transform infrared reflection-absorption spectroscopy (FT-IR RAS). Anal. Sci., 21: 215-218, 2005.
  93. Uno, K., Kuroki, Mo., Hayashi, H., Uchida, H., Kuroki, Ma. and Oshima, K.: Impairment of thrombospondin-1 expression during epithelial wound healing in corneas of vitamin A-deficient mice. Histol. Histopathol., 20: 493-499, 2005.
  94. Uchida, H., Hayashi, H., Kuroki, Mo., Uno, K., Yamada, H., Yamashita, Y., Tombran-Tink, J., Kuroki, Ma. and Oshima, K.: Vitamin A up-regulates the expression of thrombospondin-1 and pigment epithelium-derived factor in retinal pigment epithelial cells. Exp. Eye Res., 80: 23-30, 2005.
  95. Shirota, K., Tateishi, K., Koji, T., Hishikawa, Y., Hachisuga, T., Kuroki,Ma. and Kawarabayashi, T.: Early human preantral follicles have relaxin and relaxin receptor (LGR7), and relaxin promotes their development. J. Clin. Endocrinol. Metab., 90: 516-521, 2005.（A Doctor's Thesis of Shirota, K.）
  96. Kuroki, Ma., Kuroki, Mo., Shibaguchi, H., Hachimine, K. and Kinugasa, T.: Strategies for endowing cytotoxic T lymphocytes or natural killer cells with antigen-binding activity of antibodies against carcinoembryonic antigen. Tumor Biol., 25: 208-216, 2004.
  97. Kuroki, Ma., Kuroki, Mo., Shibaguchi, H., Hachimine, K., Kinugasa, T., and Badran, A.: Tumor-targeting of viral vectors for cancer gene therapy by using antibodies or their genes against tumor-associated antigens. Anticancer Res., 24: 3373-3377, 2004.
  98. Shibaguchi, H., Kuroki, Ma., Kuroki, Mo., Badran, A., Hachimine, K., and Kinugasa T.: Cloning and sequencing of variable region cDNAs of a novel human monoclonal antibody to carcinoembryonic antigen, and generation of a single chain variable fragmented antibody. Anticancer Res., 24: 3355-3360, 2004.
  99. Fujimura, S., Arakawa, F., Suzumiya, J., Yamada, Y., Liao, S., Khare, P. D., Kuroki, Ma. and Ono, J.: Growth arrest and apoptosis in adult T cell leukemia cell lines following IL-2 deprivation. Int. J. Oncol., 25: 437-443, 2004.
  100. Uno, K., Hayashi, H., Kuroki, Mo., Uchida, H., Yamauchi, Y., Kuroki, Ma. and Oshima, K.: Thrombospondin-1 accelerates wound healing of corneal epithelia. Biochem. Biophys. Res. Commun., 315: 928-934, 2004. （A Doctor's Thesis of Uno, K.）
  101. Gyobu, H., Tsuji, T., Suzuki, Y., Ohkuri, T., Chamoto, K., Kuroki, Ma., Miyoshi, H., Kawarada, Y., Katoh, H., Takeshima, T., and Nishimura, T. Generation and targeting of human tumor-specific Tc1 cells transduced with a lentivirus containing a chimeric immunoglobulin T cell receptor. Cancer Res., 64: 1490-1495, 2004.
  102. Kuroki, Ma.: Gene therapy in cancer via use of a retrovector having a tumor specificity and expressing inducible nitric oxide synthase. In: Methods in Molecular Biology, Vol. 279, Nitric Oxide Protocols (A. Hassid, ed.), Humana Press, Totowa, pp. 201-211, 2004.
  103. Nakayama, J., Tanaka, T., Furumura, M., Takahashi, A., Yamaguchi, T., Shimura, H., Ikeda, S. and Kuroki, Ma.: Inhibition of the proliferation of a malignant peripheral nerve sheath tumor cell line by gamma interferon gene transfection. J. Dermatol., 30: 879-885, 2003.
  104. Kuroki, Ma., Shibaguchi, H., Hachimine, K., Badran, A., Zhang, J. and Kuroki, Mo.: Molecular tumor markers as targets of cancer treatment: mainly on 17-1A and CEA. Mol. Tumor Marker Res., 19: 13-14, 2003.
  105. Imakiire, T., Kuroki, Mo., Shibaguchi, H., Abe, H., Yamauchi, Y., Ueno, A.,Hirose,　Y., Yamada, H., Yamashita, Y., Shirakusa, T., Ishida, I. and Kuroki, Ma.: Generation, immunologic characterization and antitumor effects of human monoclonal antibodies for carcinoembryonic antigen. Int. J. Cancer, 108: 564-570, 2004.（A Doctor's Thesis of Imakiire, T.）
  106. Kuroki, Ma.: Interview about CEA as a target. Mod. Asp. Immunobiol., 3 (2): 48, 2003.
  107. Shibaguchi, H., Arakawa, F., Imakiire, T., Kuroki, Mo. and Kuroki, Ma.: cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen, and construction of a mouse/human chimeric antibody. Anticancer Res., 23: 4383-4388, 2003.
  108. Kuroki, Ma., Shibaguchi, H., Imakiire, T., Uno, K., Shirota, K., Higuchi, T., Shitama, T., Yamada, H., Hirose, Y., Nagata, A. and Kuroki, Mo.: Immunotherapy and gene therapy of cancer using antibodies or their genes against tumor-associated antigens. Anticancer Res., 23: 4377-4381, 2003.
  109. Yamamoto, T., Senba, T., Zhang, J., Hirose, Y., Kuroki, Mo. and Kuroki, Ma.: Dialysis-based bioreactor system for the production of chimeric antibodies: an alternative to ascites production in mice. Med. Bull. Fukuoka Univ., 30: 243-247, 2003.
  110. Senba, T., Yamamoto, T., Murakami, M., Shibaguchi, H., and Kuroki, Ma.: Anti-tumor effect of an immunotoxin comprised of a chimeric anti-carcinoembryonic antigen antibody conjugated to ricin toxin A. Med. Bull. Fukuoka Univ., 30: 231-236, 2003.
  111. Fukushima, K., Ikehara, Y., Kanai, M., Kochibe, N., Kuroki, Ma. and Yamashita, K.: A b-N-acetylglucosaminyl phosphate diester residue is attached to the glycosylphosphatidylinositol anchor of human placental alkaline phosphatase. A target of the channel-forming toxin aerolysin. J. Biol. Chem., 278: 36296-36303, 2003.
  112. Fujimura, S., Suzumiya, J., Yamada, Y., Kuroki, Ma. and Ono, J. Downregulation of Bcl-xL and activation of caspases during retinoic acid-induced apoptosis in adult T-cell leukemia (ATL) cell line. Hematol. J., 4: 328-335, 2003.
  113. Li, T., Tachibana, K., Kuroki, Mo. and Kuroki, Ma.: Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovistﾑinitial results. Radiology, 229: 423-428, 2003.
  114. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Uno, K., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Thrombospondin-1 inhibits interleukin-10 release from monocytic cells through interaction with CD47. Med. Bull. Fukuoka Univ., 30: 141-147, 2003.
  115. Nakayama, J., Tanaka, T., Arakawa, F., Terao, H., Shimura, H., Ikeda, S. and Kuroki, Ma.: Gamma interferon gene transfection efficiently inhibits proliferation of neurofibroma cell lines in vitro. J. Dermatol., 30: 181-188, 2003.
  116. Kuroki, Ma., Yamauchi, Y., Beppu, R., Miyajima-Uchida, H., Uno, K., Yamada, H. and Kuroki, Mo.: Immunosuppressive functions of soluble thrombospondin-1 (TSP-1). In: Recent Research Developments in Immunology, Vol. 4 (S. G. Pandalai, ed.), Research Signpost, Korala (India), 601-614, 2002.
  117. Arakawa, F., Shibaguchi, H., Xu, Z. and Kuroki, Ma.: Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-shain anti-CEA activity. Anticancer Res., 22: 4285-4290, 2002.
  118. Kuroki, Ma., Ueno, A., Matsumoto, H., Abe, H., Li, T., Imakiire, T., Yamauchi, Y., Uno, K., Shirota, K., Shibaguchi, H. and Kuroki, Mo.: Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview. Anticancer Res. 22: 4255-4264, 2002.
  119. Bjerner, J., Lebedin, Y., Bellanger, L., Kuroki, Ma., Shively, J.E., Varaas, T., Nustad, K., Hammarstr嗄, S. and Bｿrmer, O. P.: Protein epitopes in carcinoembryonic antigen - Report from the ISOBM TD-8 workshop. Tumor Biol., 23: 249-262, 2002.
  120. Abe, H., Kuroki, Mo., Imakiire, T., Yamauchi, Y., Yamada, H., and Arakawa, F. and Kuroki, Ma.: Preparation of recombinant MK-1/Ep-CAM and establishment of an ELISA system for determining soluble MK-1/Ep-CAM levels in sera of cancer patients. J. Immunol. Methods, 270: 227-233, 2002.
  121. Zhao, L., Xu, S., Peterson, C., Kuroki, Mo., Kuroki, Ma. and Venge, P.:Purification and characterization of a 95 kDa protein―Carcinoembryonic antigen-related cell adhesion molecule 8―from normal human granulocytes. J. Immunol. Methods, 270: 27-35, 2002.
  122. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Uno, K., Abe, H., Beppu, R., Yamashita, Y., Kuroki, Ma. and Shirakusa, T.: Opposite effects of thrombospondin-1 via CD36 and CD47 on homotypic aggregation of monocytic cells. Matrix Biol., 21: 441-4448, 2002.（A Doctor's Thesis of Yamauchi, Y.）
  123. Khare, P. D., Liao, S., Hirose, Y., Kuroki, Mo., Fujimura, S., Yamauchi, Y., Miyajima-Uchida, H. and Kuroki, Ma.: Tumor growth suppression by a retroviral vector displaying scFv Antibody to CEA and Carrying the iNOS Gene. Anticancer Res., 22: 2443-2446, 2002.
  124. Matsumoto, H., Liao, S., Arakawa, F., Ueno, A., Abe, H., Awasthi, A., Kuroki, Mo. and Kuroki, Ma.: Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody. Anticancer Res., 22: 2001-2007, 2002.（A Doctor's Thesis of Matsumoto, H.）
  125. Abe, H., Kuroki, Mo., Tachibana, K., Li, T., Awasthi, A., Ueno, A., Matsumoto, H., Imakiire, T., Yamauchi, Y., Yamada, H., Ariyoshi, A. and Kuroki, Ma.: Targeted sonodynamic therapy of cancer using a photosensitizer conjugated with antibody against carcinoembryonic antigen. Anticancer Res., 22: 1575-1580, 2002.（A Doctor's Thesis of Abe, H.）
  126. Satoh, Y., Hayashi, T., Takahashi, T., Itoh, F., Adachi, M., Fukui, M., Kuroki, Mo., Kuroki, Ma., Imai, K. and Hinoda, Y.: Expression of CD66a in multiple myeloma. J. Clin. Lab. Anal., 16: 79-85, 2002.
  127. Kinugasa, T., Kuroki, Ma., Takeo, H., Kuroki, Mo., Yamashita, Y. and Shirakusa, T.: Significance of CEACAM6 in signet ring cell carcinoma of the stomach. Med. Bull. Fukuoka Univ., 29: 95-99, 2002.
  128. Ueno, A., Arakawa, F., Matsumoto, H., Imakiire, T., Uno, K., Abe, H., Miyajima-Uchida, H., Yamauchi, Y., Kuroki, Mo. and Kuroki, Ma.: Cloning and sequencing of cDNAs encoding V regions of monoclonal antibody F106-88 specific for CEACAM6 and construction of a mouse/human chimeric antibody. Med. Bull. Fukuoka Univ., 29: 83-93, 2002.
  129. Kuroki, Ma. and Yamauchi, Y.: Tumor marker CEA. Medical Clinics, 28: 1277-1279, 2002.
  130. Ueno, A., Arakawa, F., Abe, H., Matsumoto, H., Kudo, T., Asano, R., Tsumoto, K., Kumagai, I., Kuroki, Mo. and Kuroki, Ma.: T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody. Anticancer Res., 22: 769-716, 2002.（A Doctor's Thesis of Ueno, A.）
  131. Yamauchi, Y., Kuroki, Mo., Imakiire, T., Abe, H., Uchida, H., Beppu, R., Yamashita, Y., Kuroki, Ma. and Shirakusa, T.: Thrombospondin-1 differentially regulates release of IL-6 and IL-10 by human monocytic cell line U937. Biochem. Biophys. Res. Commun.: 290: 1551-1557, 2002.
  132. Jirsa, M., Muchova, L., Draberova, L., Draber, P., Smid, F., Kuroki, Ma., Marecek, Z. and Groen, A. K. Carcinoembryonic antigen-related cell adhesion molecule 1 is the 85-kilodalton pronase-resistant biliary glycoprotein in the cholesterol crystallization promoting low density protein-lipid complex. Hepatology, 34: 1075-1082, 2001.
  133. Muchova, L., Jirsa, M., Kuroki, Ma., Dudkova, L., Benes, M. J., Marecek, Z. and Smid, F. Immunoaffinity isolation of CEACAM1 on hydrazide-derivatized cellulose with immobilized monoclonal anti-CEA antibody. Biomed. Chromatogr., 15: 418-422, 2001.
  134. Kuroki, Mo., Abe, H., Imakiire, T., Liao, S., Uchida, H., Ymauchi, Y., Oikawa, S. and Kuroki, Ma.: Identification and comparison of residues critical for cell adhesion activities of two neutrophil CD66 antigens, CEACAM6 and CEACAM8. J. Leukoc. Biol., 70: 543-550, 2001.
  135. Kondo, Y., Hinoda, Y., Akashi, H., Sakamoto, H., Itoh, F., Hirata, K., Kuroki, Ma. and Imai, K.: Measurement of circulating biliary glycoprotein (CD66a) in liver diseases. J. Gastroenterol., 36: 470-475, 2001.
  136. Kuroki, Ma., Matsumoto, H., Yamauchi, Y., Tieli, L., Imakiire, T., Ueno, A., Abe, H. and Liao, S.: Diagnosis and therapy of cancer and tumor-associated antigens. Progr. Med., 21: 1911-1919, 2001.
  137. Saga, T., Sakahara, H.., Nakamoto, Y., Sato, N., Ishimori, T., Mamede, M., Kobayashi, H., Masunaga, S., Sasai, K., Kuroki, Ma. and Konishi, J.: Enhancement of the therapeutic outcome of radio-immunotherapy by combination with whole-body mild hyperthermia. Eur. J. Cancer, 37: 1429-1434, 2001.
  138. Liao, S., Khare, P. D., Kuroki, Mo., Arakawa, F., Tomita, Y., Kuroki, Ma.: Targeting of lymphokine-activated killer activity to CEA-expressing tumor cells with a recombinant fusion protein of IL-2 and anti-CEA scFv antibody. Anticancer Res., 21: 1673-1680, 2001.（A Doctor's Thesis of Liao, S.）
  139. Beppu, R. Nakamura, K., Miyajima-Uchida, H., Kuroki, Mo., Liao, S., Khare, P. D., Yamashita, Y., Shirakusa, T. and Kuroki, Ma.: Soluble thrombospondin-1 suppresses T-cell prolifiration and enhances IL-10 secretion by antigen presenting cells stimulated with phytohemagglutinin. Immunol. Invest., 30: 143-156, 2001.（A Doctor's Thesis of Beppu, R.）
  140. Khare, P. D., Liao, S., Kuroki, Mo., Hirose, Y., Arakawa, F., Nakamura, K., Tomita, Y. and Kuroki, Ma.: Specifically targeted killing carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single chain variable fragmented (scFv) antibody to CEA and carrying the gene for inducible nitric oxide synthase (iNOS). Cancer Res., 61: 370-375, 2001.
  141. Oikawa, S., Sugiyama, M., Kuroki, M., Kuroki, Ma. and Nakazato, H.: Extracellular N-domain alone is sufficient for specific heterophlic adhesion between members of carcinoembryonic antigen family, CD66b and CD66c. Biochem. Biophys. Res. Commun., 278: 564-568, 2000.
  142. Kuroki, Ma., Arakawa, F., Khare, P. D., Kuroki, M., Liao, S., Matsumoto, H., Abe, H., and Imakiire, T. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Anticancer Res., 20: 4067-4071, 2000.
  143. Egawa, K., Honda, Y., Kuroki, Ma. and Ono, T.: The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi in not expressed in blue naevuscell naevi in dendritic type. J. Cutan. Pathol., 27: 351-358, 2000.
  144. Kuroki, Ma., Liao, S., Kuroki, M., Arakawa, F., Matsumoto, H., Ueno, A., Abe, H. and Imakiire, T.: New applications of carcinoembryonic antigen (CEA) for cancer therapy. Mol. Tumor Marker Res., 15: 13-15, 2000.
  145. Egawa, K., Kuroki, Ma., Inoue, Y., and Ono, T.: Nail bed keratinocytes express an antigen of the carcinoembryonic antigen family. Br. J. Dermatol., 143: 79-83, 2000.
  146. Sato, N., Saga, T., Sakahara, H., Nakamoto, Y., Zhao, S. J., Kuroki, Ma., Iida, Y., Endo, K. and Konishi, J.: Avidin chase can reduce myelotoxicity associated with radioimmunotherapy of experimental liver micrometastases in mice. Jpn. J. Cancer Res., 91: 622-628, 2000.
  147. Tomita, Y., Arakawa, F., Hirose, Y., Liao, S., Khare, P. D., Kuroki, Mo., Yamamoto, T., Ariyoshi, A. and Kuroki, Ma.: Carcinoma-associated antigens MK-1 and CEA in urological cancers. Anticancer Res., 20: 793-798, 2000.（A Doctor's Thesis of Tomita, Y.）
  148. Watanabe, N., Oriuchi, N., Endo, K., Inoue, T., Kuroki, Ma., Matsuoka, Y., Tanada, S., Murata, H., Kim, E. E., Sasaki, Y.: Use of CaNa2EDTA for improvement of radioimmunodetection and radioimmunotherapy with In-111 and Yttrium-90-DTPA-anti-CEA MAbs in nude mice bearing human colorectal cancer. J. Nucl. Med., 41: 337-344, 2000.
  149. Tomita, Y., Arakawa, F., Yamamoto, T., Kuwahara, M., Watanabe, R., Iwasaki, H., Kikuchi, M. and Kuroki, Ma.: Molecular identification of a human adenocarcinoma-associated glycoprotein recognized by mouse monoclonal antibody FU-MK-1. Jan. J. Cancer Res., 91: 231-238, 2000.（A Doctor's Thesis of Tomita, Y.）
  150. Miyajima-Uchida, H., Hayashi, H., Beppu, R., Kuroki, Mo., Fukami, M., Arakawa, F., Tomita, Y., Kuroki, Ma. and Oshima, K.: Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 41: 561-567,2000.（A Doctor's Thesis of Uchida, H.）
  151. Kuroki, Ma., Matsumoto, Y., Kobayashi, N., Yamada, K., Matsushita, H., Nozawa, M., Yamamoto, T., Tomita, Y., Beppu, R., Nakamura, K. and Hirose, Y.: Nonspecific cross-reacting antigen-50/90 (NCA-50/90) as a new tumor marker. Anticancer Res., 19: 5599-5606. 1999.
  152. Nakamura, K., Yuh, K. and Kuroki, Ma.: Immunosuppressive effects of apoptosis; T cell anergy induced by apoptotic cells or apoptotic bodies. In: Recent Research Developments in Immunology, Vol. 1 (S. G. Pandalai, ed.), Research Signpost, Trivandrum, pp. 21-30, 1999.
  153. Karube, Y., Katsuno, K., Ito, S., Matsunaga, K., Takata, J., Kuroki, Ma., Murakami, M. and Matsuoka, Y.: Tumor scintigraphy by the method for subtracting the initial image with technetium-99m labeled antibody. Ann. Nucl. Med.,13: 407-413, 1999.
  154. Kuroki, Ma., Xu, Z., Senba, T. and Arakawa, F.: Missile therapy and immunogene therapy for cancer using carcinoembryonic antigen (CEA) as a target. In: Recent Research Developments in Immunology, Vol. 1 (S. G. Pandalai, ed.), Researcg Signpost, Trivandrum, pp. 1-8, 1999.
  155. Emi, K., Nakamura, K., Yuh, K., Sugyo, S., Shijo, H., Kuroki, Ma. and Tamura, K.: Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus. J. Gastroenterol. Hepatol., 14: 1018-1024, 1999.
  156. Yamamoto, T., Arakawa, F., Senba, T., Nakamura, K., Kuwahara, M., Kuroki, Mo., Ikeda, S. and Kuroki, Ma.: Enhanced antitumor activity of a combination treatment with a mouse/human chimeric anti-MK-1 antibody and lymphokine-activated killer cells in vitro and in severe combined immunodeficient mouse xenograft model. Cancer Immunol. Immunother., 48: 165-171, 1999.（A Doctor's Thesis of Yamamoto, T.）
  157. Arakawa, F. and Kuroki, Ma.: Chimeric MAb Ch FU-MK-1. Hybridoma, 18: 216，1999.
  158. Sugita, K., Mori, T., Yokota, S., Kuroki, Ma., Koyama, O., T., Inukai, T., Iijima, K., Goi, K., Tezuka, T., Kojika, S., Kagami, K. and Nakazawa S.: The SA3544 antigen predominantly expressed on surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells. Leukemia, 13: 779-785, 1999.
  159. Watanabe, N., Oriuchi, N., Sugiyama, S., Kuroki, Ma., Matsuoka, Y., Tanada, S., Murata, H., Inoue, T. and Sasaki, Y.: In vitro and in vivo comparison of binding of 99m-Tc-labeled anti-CEA MAb F33-104 with 99m-Tc-labeled anti-CEA MAb BW431/26. Nuklearmedizin, 38: 115-119, 1999.
  160. Sato, N., Saga, T., Sakahara, H., Yao, A., Nakamoto, Y., Ahang, M., Kuroki, Ma., Matsuoka, Y., Iida Y. and Konishi, J.: Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. J. Nucl. Med., 40: 685-692, 1999.
  161. Nakamura, K., Yuh, K., Sugyo, S., Kuroki, Ma., Shijo, H. and Tamura, K.: Unresponsiveness of peripheral T cells induced by intrusion of apoptotic bodies derived from autologous T cells. Cell. Immunol., 193: 147-154, 1999.
  162. Arakawa, F., Yamamoto, T., Kanda, H., Watanabe, T. and Kuroki, Ma.: cDNA sequence analysis of the variable domains of monoclonal antibody FU-MK-1 specific for a transmembrane carcinoma-associated antigen, and construction of a mouse/human chimeric antibody. Hybridoma, 18: 131-138, 1999.
  163. Saga, T., Sakahara, H., Nakamoto, Y., Sato, N., Zhao, S., Iida, Y., Kuroki, Ma., Endo, K. and Konishi, J.: Radioimmunotherapy for liver micrometastases in mice: pharmacokinetics, does estimation, and long-term effect. Jpn. J. Cancer Res., 90: 342-348, 1999.
  164. Kuroki, Ma., Xu, Z., Senba, T., Arakawa, F. and Tomita, Y.: Immunotherapy and immunogene therapy for cancer using carcinoembryonic antigen (CEA) as the target. In: Proceedings of the 1st Immunomodulation Research Center (IRC) Symposium: Trends in Immunomodulation (B. S. Kwon, ed.), Ulsan Univ. Press, Ulsan (Korea), pp.13-25, 1998.
  165. Egawa, M., Honda, Y., Ono, T., Kitasato, H. and Kuroki, Ma.: The glycoprotein of the carcinoembryonic antigen (CEA) fgamily expressed on epithelial keratinocytes in viral warts. Arch. Dermatol. Res., 290: 453-457, 1998.
  166. Kuroki, Ma., Senba, T., and Ymamamoto, T.: Mouse/human chimeric antibodies and related engineered antibodies. Clin. Immunol., 30: 947-955, 1998.
  167. Egawa, K., Honda, Y., Kuroki, Ma., and Ono, T.: Immunohistochemical demonstration of carcinoembryonic antigen and related antigens in various cutaneous keratinous neoplasms and verruca vulgaris. Br. J. Dermatol., 139: 178-185, 1998.
  168. Kuroki, Ma., Ymamamoto, T., and Senba, T.: Several new applications of the tumor-associated antigen CEA. Progr. Med., 18: 1063-1068, 1998.
  169. Senba, T., Kuroki, Ma., Arakawa, F., Yamamoto, T., Kuwahara, M., Haruno, M., Ikeda, S., and Matsuoka, Y.: Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Anticancer Res., 18: 17-24, 1998.（A Doctor's Thesis of Senba, T.）
  170. Kuroki, Ma., Yamamoto, T., Senba, T., Xu, Z., Tomita, Y., Beppu, R., Arakawa, F. and Haruno, M.: Future perspectives of immunodiagnosis and immunotherapy of cancer using CEA gene family. Mol. Tumor Marker Res., 13: 29-31, 1998.
  171. Honda, Y., Egawa, K., Kuroki, Ma., and Ono, T.: Hair cycle-dependent expression of a nonspecific cross reacting antigen (NCA)-50/90-like molecule on follicular keratinocytes. Arch. Dermatol. Res., 289: 457-465, 1997.
  172. Murakami, M., Kuroki, Ma., Arakawa, F., Haruno, M., Kuwahara, M., Ozaki, H., Senba, T., and Matsuoka, Y.: Binding reactivity of monoclonal anti-carcinoembryonic antigen (CEA) antibodies with cell membrane-bound CEA and with free CEA in solution. Immunol. Invest., 25: 23-35, 1996.
  173. Matsushita, H., Jingzhi, X., Kuroki, Ma., Kondo, A., Inoue, E., Teramura, Y., Nozawa, M., Senba, T., Yamamoto, T., and Matsuoka, Y.: Establishment and evaluation of a new chemiluminescent enzyme immunoassay for carcinoembryonic antigen adapted to the fully automated ACCESS system. Eur. J. Clin. Chem. Clin. Biochem., 34: 829-835, 1996.
  174. Kuwahara, M., Kuroki, Ma., Arakawa, F., Senba, T., Matsuoka, Y., Hideshima, T., Yamashita, Y., and Kanda, H.: A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res., 16: 2661-2667, 1996.（A Doctor's Thesis of Kuwahara, M.）
  175. Haruno, M., Kuroki, Ma., Matsunaga, K., Takata, J., Karube, Y., Senba, T., Murakami, M., Arakawa, F., Kuwahara, M., Ozaki, H., Matsuoka, Y., Kanda, H., and Watanabe, T.: Tumor-specific accumulation of 125I-labeled mouse-human chimeric anti-CEA antibody in a xenografted human cancer model demonstrated by whole-body autoradiography and immunostaining. Nucl. Med. Biol., 23: 821-826, 1996.
  176. Kuroki, Ma.: A simple solid-phase competition assay with labeled antigen. In: Methods in Molecular Biology, Vol. 66, Epitope Mapping Protocols (G.E. Morris, ed.), Humana Press, Totowa, pp. 47-53, 1996.
  177. Arakawa, F., Kuroki, Ma., Kuwahara, M., Senba, T., Ozaki, H., Matsuoka, Y., Misumi, Y., Kanda, H., and Watanabe, T.: Cloning and sequencing of the VH and Vkappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J. Biochem., 120: 657-662, 1996.（A Doctor's Thesis of Arakawa, F.）
  178. Egawa, K., Honda, Y., Kuroki, Ma., Inaba, Y., and Ono, T.: Carcinoembryonic antigen and related antigens expressed on keratinocytes in inflammatory dermatoses. Br. J. Dermatol., 134: 451-459, 1996.
  179. Karube, Y., Katsuno, K., Takata, J., Matsunaga, K., Haruno, M., Kuroki, Ma., Arakawa, F., Matsuoka, Y. and Kanda, H.: Radioimmunoscintigraphy using technetium-99m labeled parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen in athymic nude mice bearing tumor. Nucl. Med. Biol., 23: 753-759, 1996.
  180. Kuroki, Ma., Arakawa, F., and Haruno, M.: Construction and clinical application of chimeric antibodies. Jpn. J. Clin. Med., 53: 3122-3131, 1995.
  181. Fukushima, K., Ohkura, T., Kanai, M., Kuroki, Ma., Matsuoka, Y., Kobata, A. and Yamashita, K.: Carbohydrate structures of a normal counterpart of the carcinoembryonic antigen produced by colon epithelial cells of normal adults. Glycobiology, 5: 105-115, 1995.
  182. Kuroki, Ma. and Kuwahara, M.: Future perspectives of clinical application of CEA gene family. J. Clin. Exp. Med., 175: 731-735, 1995.
  183. Yamashita, K., Fukushima, K., Sakiyama, T., Murata, F., Kuroki, Ma., and Matsuoka, Y.: Expression of Siaa2ｮ6Galb1ｮ4GlcNAc residues on carbohydrate moieties of carcinoembryonic antigens produced by human colon adenocarcinoma. Cancer Res., 55:1675-1679, 1995.
  184. Kuroki, Ma.: Antigenicity and assay methods of CEA. Mod. Med. Lab., 23: 845-852, 1995.
  185. Kuroki, Ma., Matsumoto, Y., Arakawa, F., Haruno, M., Murakami, M., Kuwahara, M., Ozaki, H., Senba, T., and Matsuoka, Y.: Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/ mouse chimeric antibody to CEA as the tracer. J. Immunol. Methods, 180: 81-91, 1995.
  186. Kuroki, Ma.: New sandwich-type enzyme immunoassay for carcinoembryonic antigen that eliminates interference from heterophilic antibodies by using a human/mouse chimeric antibody as the tracer. In: Quality Control in the Clinical Laboratory '95 (Y. Ohba, T. Kanno, H. Okabe, M. Totani, K. Nakahara, K. Ichihara, K. Kumasaka and H. Kanno, eds.), Excerpta Medica, Tokyo, pp. 143-149, 1995.
  187. Murakami, M., Kuroki, Ma., Arakawa, F., Oikawa, S., Nakazato, H., and Matsuoka, Y.: A reference of the Gold classification of monoclonal antibodies against carcinoembryonic antigen to the domain structure of the carcinoembryonic antigen molecule. Hybridoma, 14: 19-28, 1995.（A Doctor's Thesis of Murakami, M.）
  188. Kobata, A., Matsuoka, Y., Kuroki, Ma., and Yamashita, K.: The sugar cahin structures of carcinoembryonic antigens and related normal antigens. Pure Appl. Chem., 67: 1689-1698, 1995.
  189. Kuroki, Ma., Arakawa, F. and Haruno, M.: Construction and clinical application of chimeric antibodies. Jpn. J. Clin. Med., 53: 3122-3131, 1995.
  190. Kuroki, Ma.: A simple solid-phase mutual inhibition assay using biotinylated antigen for analyzing the epitope specificities of monoclonal antibodies. In: Cell Biology: A Laboratory Handbook, Vol. 2 (J. E. Celis, ed.), Academic Press, New York, pp. 329-334, 1994.
  191. Kuwahara, M., Kuroki, Ma., Haruno, M., Murakami, M., Arakawa, F., Oikawa, S., Nakazato, H., and Matsuoka, Y.: A rapid colorimetric assay for carcinoembryonic antigen (CEA)-mediated cell adhesion and analysis of CEA domains involved in the adhesion. Immunol. Invest., 23: 367-380, 1994.
  192. Haruno, M., Kuroki, Ma., Arakawa, F., Kanda, H., Watanabe, T., and Matsuoka, Y.: In vitro and in vivo characterization of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen. Antibody, Immunoconj. Radiopharm., 7: 133-148, 1994.（A Doctor's Thesis of Haruno, M.）
  193. Kuroki, Ma., Kuwahara, M., Murakami, M., Matsumoto, Y., and Matsuoka, Y.: Fractionation of carcinoembryonic antigen and related antigens in normal adult feces using a gradeint medium Percoll. Prep. Biochem., 24: 25-40, 1994.
  194. Kuroki, Ma.: Molecular aspects and usefulness of a tumor marker CA72-4 (TAG-72). Immunonucl. Med., 8: 8-10, 1993.
  195. Nagasaki, H., Watanabe, S., Kuroki, Ma., Matsumoto, Y., Murakami, M., Omoda, N., Kondo, N., Jinnai, H., Takaoka, H., and Matsuoka, Y.: An enzyme immunoassay for carcinoembryonic antigen (CEA) with homogeneous reactivity to different CEA preparations and low cross-reactivity with CEA-related normal antigens. J. Immunol. Methods, 162: 235-245, 1993.（A Doctor's Thesis of Nagasaki, H.）
  196. Kuroki, Ma.: Immunochemical and molecular biological aspects of carcino-embryonic antigen CEA. Immunonucl. Med., 8: 2-7, 1993.
  197. Kuroki, Ma., Kuwahara, M., Tsuruta, Y., Murakami, M., and Matsuoka, Y.: Effective purification of nonspecific cross-reacting antigens with phosphatidylinositol-specific phospholipase C. Prep. Biochem., 23: 333-349, 1993.
  198. Kuroki, Ma. and Matsuoka, Y.: Chimeric monoclonal antibodies Ch F11-35 and Ch F11-39 against CEA. Monocl. Abs., 11: 15-16, 1993.
  199. Arakawa, F., Haruno, M., Kuroki, Ma., Kanda, H., Watanabe, T., Misumi, Y., and Matsuoka, Y.: Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen. Hybridoma, 12: 365-379, 1993.（A Doctor's Thesis of Arakawa, F.）
  200. Schlom, J., Colcher, D., Milenic, D. E., Horan Hand, P., Greiner, J. W., Kuroki, Ma., Thor, A., Molinolo, A. and Ohuchi, N.: TAG-72 as a tumor marker. In: Serological Cancer Markers: Diagnosis, Prognosis, and Monitoring (S. Sell, ed.), Humana Press, Totowa, pp. 387-416, 1992.
  201. Kuroki, Ma.: Molecular aspects and clinical application of CEA. Monthly Book Gastroenterol, 2: 31-43, 1992.
  202. Kuroki, Ma., Wakisaka, M., Murakami, M., Haruno, M., Arakawa, F., Higuchi, H., and Matsuoka, Y.: Determination of epitope specificities of a large number of monoclonal antibodies by solid-phase mutual inhibition assays using biotinylated antigen. Immunol. Invest., 21: 523-538, 1992.
  203. Kuroki, Ma.: Molecular aspects and possible applications of CA72-4 (TAG-72). Progr. Med., 12: 699-708, 1992.
  204. Kuroki, Ma., Murakami, M., Wakisaka, M., Ikeda, S., Oikawa, S., Oshima, T., Nakazato, H., Kosaki, G., and Matsuoka, Y.: Immunoreactivity of recombinant carcinoembryonic antigen proteins expressed in Escherichia coli. Immunol. Invest., 21: 241-257, 1992.
  205. Kuroki, Ma., Haruno, M., Arakawa, F., and Matsuoka, Y.: Evaluation of seven commercially available enzyme immunoassay kits for carcinoembryonic antigen (CEA) using purified CEA and normal related antigens. In: Quality Control in the Clinical Laboratory '91 (T. Kawai, Y. Ohba, T. Kanno, K. Kawano, K. Ueda and E. Tatsumi, eds.), Excerpta Medica, Tokyo, pp. 180-186, 1992.
  206. Kuroki, Ma., Haruno, M., Arakawa, F., Wakisaka, M., and Matsuoka, Y.: Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analyzed with purified preparations of CEA and related normal antigens. Clin. Biochem., 25: 29-35, 1992.
  207. Kuroki, Ma., Haruno, M., Murakami, M., Wakisaka, M., Oikawa, S., Nakazato, H., and Matsuoka, Y.: Epitope mapping of the nonspecific cross-reacting antigen using various related recombinant proteins expressed in Chinese hamster ovary cells and eight distinct monoclonal antibodies. Immunol. Invest., 21: 143-158, 1992.
  208. Ikeda, S., Kuroki, Ma., Haruno, M., Oikawa, S., Nakazato, H., Kosaki, G., and Matsuoka, Y.: Epitope mapping of the carcinoembryonic antigen with various related recombinant proteins expressed in Chinese hamster ovary cells and 25 distinct monoclonal antibodies. Molec. Immunol., 29: 229-240, 1992.（A Doctor's Thesis of Ikeda, S.）
  209. Kuroki, Ma. and Matsuoka, Y.: Monoclonal antibodies to CEA. Monocl. Abs., 10: 41-42, 1992.
  210. Kuroki, Ma., Arakawa, F., Haruno, M., Murakami, M., Wakisaka, M., Higuchi, H., Oikawa, S., Nakazato, H., and Matsuoka, Y.: Biochemical characterization of 25 distinct carcinoembryonic antigen (CEA) epitopes recognized by 57 monoclonal antibodies and categorized into seven groups in terms of domain structure of the CEA molecule. Hybridoma, 11: 391-407, 1992.
  211. Kuroki, Ma., Murakami, M., Wakisaka, M., Krop-Watorek, A., Oikawa, S., Nakazato, H., Kosaki, G., and Matsuoka, Y.: Epitopes predominantly retained on the carcinoembryonic antigen molecules in plasma of patients with malignant tumors but not on those in plasma of normal individuals. Jpn. J. Cancer Res., 83: 505-514, 1992.
  212. Horan Hand, P., Simpson, J. F., Kuroki, Ma., Parker, R., and Schlom, J.: Reactivities of an anti-CEA peptide monoclonal antibody. Int. J. Biol. Markers, 7: 1-15, 1992.
  213. Matsuoka, Y. and Kuroki, Ma.: Monoclonal antibodies to NCA. Monocl. Abs., 9: 5-6, 1991.
  214. Kuroki, Ma., Arakawa, F., Higuchi, H., Haruno, M., Wakisaka, M., and Matsuoka, Y.: Immunological and biochemical characterization of the nonspecific cross-reacting antigen epitopes using twenty-three monoclonal antibodies. Hybridoma, 10: 557-574, 1991.
  215. Kuroki, Ma.: Problems and utilities of current tumor markers for digestive system. Oncologia, 24: 24-32, 1991.
  216. Matsuoka, Y.,Matsuo, Y., Okamoto, N., Kuroki, Mo., Kuroki, Ma. and Ikehara, Y.: Highly effective extraction of carcinoembryonic antigen with phosphatidylinositol-specific phospholipase C. Tumor Biol., 12: 91-98, 1991.
  217. Kuroki, Ma.: Current problems on assay systems for tumor markers with particular reference to CEA assay systems. Progr. Med., 11: 155-167, 1991.
  218. Tsutsumi, Y., Onoda, N., Misawa, M., Kuroki, Ma. and Matsuoka, Y.: Immunohistochemical demonstration of nonspecific cross-reacting antigen in normal and neoplastic human tissues using a monoclonal antibody: Comparison with carcinoembryonic antigen localization. Acta Pathol. Jpn., 40: 85-97, 1990.
  219. Watanabe, Y., Endo, K., Saga, T., Koizumi, M., Sakahara, H., Nakai, T., Hosono, M., Yao, Z.-S., Kuroki, Ma., Matsuoka, Y. and Konishi, J.: Influence of cocktails of labeled monoclonal antibodies on the localization of antibodies in human tumor xenografts. Jpn. J. Cancer Res., 81: 266-271, 1990.
  220. Kuroki, Ma. and Matsuoka, Y.: Tumor markers for gastro-intestinal cancers. II. Main tumor markers. (2) Carcinoembryonic antigen CEA. Clin. Gastroenterol., 5: 335-346, 1990.
  221. Matsuoka, Y., Matsuo, Y., Sugano, K., Ohkura, H., Kuroki, Mo. and Kuroki, Ma.: Characterization of carcinoembryonic antigen-related antigens in normal adult feces. Jpn. J. Cancer Res., 81: 514-519, 1990.
  222. Kuroki, Mo., Matsuo, Y., Ohtani, T., Minowada, J., Kuroki, Ma. and Matsuoka, Y.: A novel CEA-cross-reacting antigen of Mr 140,000 expressed on human lymphoid cell lines. Molec. Immunol., 27: 689-696, 1990.
  223. Kuroki, Ma., Fernsten, P. D., Wunderlich, D., Colcher, D., Simpson, J. F., Poole, D. J., and Schlom, J.: Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. Cancer Res., 50: 4872-4879, 1990.
  224. Kuroki, M., Matsuo, Y., Kuroki, Ma., and Matsuoka, Y.: Nonspecific cross-reacting antigen (NCA) expressed by human granulocytes: Six species with different peptide sizes and membrane anchoring forms. Biochem. Biophys. Res. Commun., 166: 701-708, 1990.
  225. Kobata, A., Totani, K., Endo, T., Kuroki, Ma., Matsuoka, Y. and Yamashita, K.: Comparative study of the sugar chains of carcinoembryonic antigen and its crossreacting antigen purified from meconium. In: The Carcinoembryonic Antigen Gene Family (A. Yachi and J. E. Shively, eds.), Elsevier Science Publishers, Amsterdam, pp. 12-22, 1989.
  226. Watanabe, Y., Endo, K., Koizumi, M., Kawamura, Y., Saga, T., Sakahara, H., Kuroki, Ma., Matsuoka, Y. and Konishi, J.,: Effect of tumor mass and antigenic nature of the biodistribution of labeled monoclonal antibodies in mice. Cancer Res., 49: 2884-2889, 1989. 1989.
  227. Yamashita, K., Totani, K., Iwaki, Y., Kuroki, Ma., Matsuoka, Y., Endo, T. and Kobata, A.: Carbohydrate structures of nonspecific cross-reacting antigen-2, a glycoprotein purified from meconium as an antigen cross-reacting with anticarcinoembryonic antigen antibody: Occurrence of complex-type sugar chains with the Galb1ｮ3GlcNAcb1ｮ3Galb1ｮ4GlcNAcb1ｮouter chains. J. Biol. Chem., 264: 17873-17881, 1989.
  228. Ohbayashi, H., Endo, T., Yamashita, K., Kuroki, Ma., Matsuoka, Y. and Kobata, A.: Novel methods to determine the epitopes on the asparagine-linked oligosaccharides of glycoproteins. Anal. Biochem., 182: 200-206, 1989.
  229. Suemizu, H., Tsutsumi, Y., Watanabe, K., Kuroki, Ma. and Matsuoka, Y.: Alterations in nonspecific cross-reacting antigen localization during cell culture. An immunoelectron microscopic study using a human adenocarcinoma cell line. Acta Pathol. Jpn., 39: 772-778, 1989.
  230. Kuroki, Ma., Greiner, J. W., Simpson, J. F., Primus, F. J., Guadagni, F., and Schlom, J.: Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. Int. J. Cancer, 44: 208-218, 1989.
  231. Muraro, R., Kuroki, Ma., Wunderlich, D., Poole, D. J., Colcher, D., Thor, A., Greiner, J. W., Simpson, J. F., Molinolo, A., Noguchi, P., and Schlom, J.: Generation and characterization of B72.3 second generation monoclonal antibodies reactive with tumor-associated glycoprotein 72 antigen. Cancer Res., 48: 4588-4596, 1988.
  232. Matsuoka, Y., Kuroki, Ma., Okamoto, N., Ikeda, S., Hara, Y., Minamizawa, T., Tachibana, S., Ogawa, H., and Tabata, N.: Evaluation of a new monoclonal radioimmunoassay system for carcinoembryonic antigen. Jpn. J. Clin. Oncol., 18: 97-103, 1988.
  233. Kuroki, M., Kuroki, Ma., Moore, J. E., Ichiki, S., and Matsuoka, Y.: The molecular heterogeneity of nonspecific cross-reacting antigen synthesized by tumor cells and granulocytes. Jpn. J. Cancer Res., 79: 82-90, 1988.
  234. Suzuki, N., Kondo, K., Tominaga, S., Kuroki, Ma. and Matsuoka, Y.: Heterogeneity of circulating carcinoembryonic antigen analyzed by sandwich-enzyme immunoassays with different specificities. Cancer Res., 47: 4782-4787, 1987.
  235. Kuroki, Ma., Arakawa, F., Higuchi, H., Matsunaga, A., Okamoto, N., Takakura, K., and Matsuoka, Y.: Epitope mapping of the carcinoembryonic antigen by monoclonal antibodies and establishment of a new improved radioimmunoassay system. Jpn. J. Cancer Res., 78: 386-396, 1987.
  236. Matsunaga, A., Kuroki, Ma., Higuchi, H., Arakawa, F., Takakura, K., Okamoto, N., and Matsuoka, Y.: Antigenic heterogeneity of carcinoembryonic antigen (CEA) in the circulation defined by monoclonal antibodies against the carbohydrate moiety of CEA and closely related antigens. Cancer Res., 47: 56-61, 1987.（A Doctor's Thesis of Matsunaga, A.）
  237. Yamashita, K., Totani, K., Kuroki, Ma., Matsuoka, Y., Ueda, I., and Kobata, A.: Structural studies of the carbohydrate moieties of carcinoembryonic antigens. Cancer Res., 47: 3451-3459, 1987.
  238. Ichiki, S., Kuroki, Ma., Matsunaga, A., Arakawa, F., Okamoto, N., and Matsuoka, Y.: Antigenic alterations of carcinoembryonic antigen involved in the secretion from various human tumor cell lines. Jpn. J. Cancer Res., 77: 1005-1011, 1986.
  239. Ichiki, S., Kuroki, Ma., Kuroki, M., Koga, Y., and Matsuoka, Y.: Production kinetics and immunochemical properties of carcinoembryonic antigen and nonspecific cross-reacting antigen synthesized by various human tumor cell lines. Jpn. J. Cancer Res., 77: 462-472, 1986.（A Doctor's Thesis of Ichiki, S.）
  240. Kuroki, Ma. and Matsuoka, Y.: Basic aspects of CEA. J. Clin. Exp. Med., 137: 358-360, 1986.
  241. Ichiki, S., Kuroki, Ma., Matsunaga, A., Kuroki, M., and Matsuoka, Y.: Production of immunoreactive calcitonin and some other tumor markers by established human tumor cell lines. Jpn. J. Cancer Res., 77: 270-275, 1986.
  242. Kuroki, Ma. and Matsuoka, Y.: Immunodiagnosis of cancer by using carcinoembryonic antigen (CEA). Immunopharmacol. Ther., 4: 515-519, 1986.
  243. Koga, Y., Kuroki, Ma., Matsunaga, A., Shinoda, T., Takayasu, T., and Matsuoka, Y.: Further comparative studies on chemical properties of carcinoembryonic antigen in tumor tissues and closely related antigens in adult feces and meconium. Molec. Immunol., 22: 67-73, 1985.
  244. Yamashita, K., Ueda, I., Kuroki, Ma., Matsuoka, Y. and Kobata, A.: Carcino-embryonic antigen has asparagine-linked sugar chains containing blood group-related antigenic determinants. In: "Glycoconjugates" Proceedings of the VIIIth International Symposium, Vol. 2 (E. A. Davidson, J. C. Williams and N. M. DiFerrante, eds.), Praeger Scientific, New York, pp. 441-442, 1985.
  245. Kuroki, Ma., Koga, Y., and Matsuoka, Y.: Monoclonal antibodies to carcinoembryonic antigen: A systematic analysis of antibody specificities by using related normal antigens and evidence for allotypic determinants on carcinoembryonic antigen. J. Immunol., 133: 2090-2097, 1984.
  246. Kuroki, M., Kuroki, Ma., Ichiki, S., and Matsuoka, Y.: Identification and partial characterization of the unglycosylated peptide of carcinoembryonic antigen synthesized by human tumor cell lines in the presence of tunicamycin. Molec. Immunol., 21: 743-746, 1984.
  247. Kuroki, Ma., Yamaguchi, A., Koga, Y., and Matsuoka, Y.: Antigenic reactivities of purified preparations of carcinoembryonic antigen (CEA) and related normal antigens using four different radioimmunoassay systems for CEA. J. Immunol. Methods, 60: 221-233, 1983.
  248. Matsuoka, Y., Kuroki, Ma. Koga, Y., Ogawa, H., Nakazawa, N., Tachibana, S., and Minamizawa, T.: A new direct solid-phase radioimmunoassay for carcinoembryonic antigen without pretreatment of serum samples. J. Immunol. Methods, 58: 31-47, 1983.
  249. Kuroki, Ma. and Matsuoka, Y.: CEA - chemistry and biology. Immunol. Dis., 4: 723-735, 1982.
  250. Matsuoka, Y., Kuroki, Ma., Koga, Y., Ohmaru, A., Miyauchi,T. and Ono, Y.: New method of blood carcinoembryonic antigen (CEA) analysis. Preliminary evaluation and clinical application of CEA kit "Daiichi". Jpn. J. Nucl. Med., 19: 1023-1033, 1982.
  251. Kuroki, Ma., Ichiki, S., Kuroki, M., and Matsuoka, Y.: Coproduction of carcinoembryonic antigen and nonspecific cross-reacting antigen by a continuous cell line from a human pancreatic tumor. J. Natl. Cancer Inst., 69: 401-408, 1982.
  252. Kuroki, Ma. and Matsuoka, Y.: Carcinoembryonic antigen (CEA) - experimental studies. Jpn. J. Clin. Pathol., Suppl. 51: 22-37, 1982.
  253. Kuroki, Ma., Shinoda, T., Takayasu, T., Koga, Y., and Matsuoka, Y.: Immunological characterization and structural studies of normal fecal antigen-1 related to carcinoembryonic antigen. Molec. Immunol., 19: 399-406, 1982.
  254. Matsuoka, Y., Kuroki, Ma., Koga, Y., Kuriyama, H., Mori, T., and Kosaki, G.: Immunochemical differences among carcinoembryonic antigen in tumor tissues and related antigens in meconium and adult feces. Cancer Res., 42: 2012-2018, 1982.（A Doctor's Thesis of Kuriyama, H.）
  255. Kuroki, Ma. and Matsuoka, Y.: Immunological aspects of carcinoembryonic antigen. Metabol. Dis., 18: 717-729, 1981.
  256. Kuroki, Ma., Koga, Y., and Matsuoka, Y.: Purification and characterization of carcinoembryonic antigen-related antigens in normal adult feces. Cancer Res., 41: 713-720, 1981. (A Doctor's Thesis of Kuroki, Ma.)
  257. Saito, T., Kuroki, Ma. and Kishimoto, S.: Surface markers and functions of human lymphocytes. J. Clin. Sci., 14: 431-441, 1978.
  258. Kishimoto, S., Tomino, S., Inomata, K., Kotegawa,S., Saitoh, T., Kuroki, Ma., Mitsuya, H. and Hisamitsu, S.: Age-related changes in the subsets and functions of human T lymphocytes. J. Immunol., 121: 1773-1780, 1978.

Updated: Dec 1, 2011.

Return to [Department of Biochemistry (English) or (Japanese)]